Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10.1038/nrc2602
   PubMed Web of Science ®Google Scholar
• Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother 2014; 15:407-20; PMID:24369047; http://dx.doi.org/10.1517/14656566.2014.870555
   PubMed Web of Science ®Google Scholar
• Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget 2015; 6(5):3033-42; PMID:25596748.
   Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-83; PMID:16603719; http://dx.doi.org/10.1200/JCO.2005.03.7689
   PubMed Web of Science ®Google Scholar
• Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013; 19:5320-8; PMID:24089445; http://dx.doi.org/10.1158/1078-0432.CCR-13-0259
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, Storlazzi CT, Ottaviani E, Cattina F, Impera L, et al. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res 2011; 17:7413-23; PMID:22134481; http://dx.doi.org/10.1158/1078-0432.CCR-11-1227
   PubMed Web of Science ®Google Scholar
• Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T, Yamamoto K. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999; 5:4152-7; PMID:10632354
   PubMed Web of Science ®Google Scholar
• Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J, Chen M. The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 2013; 108:2542-8; PMID:23703248; http://dx.doi.org/10.1038/bjc.2013.251
   PubMed Web of Science ®Google Scholar
• Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005; 23:8853-62; PMID:16314645; http://dx.doi.org/10.1200/JCO.2005.02.8589
   PubMed Web of Science ®Google Scholar
• Peurala E, Koivunen P, Haapasaari KM, Bloigu R, Jukkola-Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 2013; 15:R5; PMID:23336272; http://dx.doi.org/10.1186/bcr3376
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. AACR Annual Meeting Abstract # CT101
   Google Scholar
• Infante JR, Shapiro G, Witteveen P, Gerecitano JF, Ribrag V, Chugh R, Issa I, Chakraborty A, Matano A, Zhao X. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. ASCO Annual Meeting Proceedings, 2014:2528
   Google Scholar
• Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 2014; 14:169-76; PMID:24393852; http://dx.doi.org/10.1016/j.clbc.2013.10.016
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O'Dwyer PJ, Schwartz GK. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18:568-76; PMID:22090362; http://dx.doi.org/10.1158/1078-0432.CCR-11-0509
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119:4597-607; PMID:22383795; http://dx.doi.org/10.1182/blood-2011-10-388298
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011; 104:1862-8; PMID:21610706; http://dx.doi.org/10.1038/bjc.2011.177
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-8; PMID:18772890; http://dx.doi.org/10.1038/nature07385
   PubMed Web of Science ®Google Scholar
• Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54:6353-8; PMID:7987828
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64:6892-9; PMID:15466178; http://dx.doi.org/10.1158/0008-5472.CAN-04-1337
   PubMed Web of Science ®Google Scholar
• Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54:6321-4; PMID:7987821
   PubMed Web of Science ®Google Scholar
• Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, Waldman T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010; 70:3228-38; PMID:20354191; http://dx.doi.org/10.1158/0008-5472.CAN-09-4559
   PubMed Web of Science ®Google Scholar
• Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Dis 2013; 3:35-43; PMID:23208470; http://dx.doi.org/10.1158/2159-8290.CD-12-0361
   PubMed Web of Science ®Google Scholar
• Nagl NG, Jr., Patsialou A, Haines DS, Dallas PB, Beck GR, Jr., Moran E. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 2005; 65:9236-44; PMID:16230384; http://dx.doi.org/10.1158/0008-5472.CAN-05-1225
   PubMed Web of Science ®Google Scholar
• Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413:83-6; PMID:11544530; http://dx.doi.org/10.1038/35092584
   PubMed Web of Science ®Google Scholar
• Akervall J, Bockmuhl U, Petersen I, Yang K, Carey TE, Kurnit DM. The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003; 9:1750-5; PMID:12738730
   PubMed Web of Science ®Google Scholar
• Kawauchi T, Shikanai M, Kosodo Y. Extra-cell cycle regulatory functions of cyclin-dependent kinases (CDK) and CDK inhibitor proteins contribute to brain development and neurological disorders. Genes Cell 2013; 18:176-94; http://dx.doi.org/10.1111/gtc.12029
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79; PMID:14576837; http://dx.doi.org/10.1038/sj.onc.1206933
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst 2014; 106:dju057; PMID:24681605; http://dx.doi.org/10.1093/jnci/dju057
   PubMedGoogle Scholar
• Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014; 6:377-87; PMID:24440717; http://dx.doi.org/10.1016/j.celrep.2013.12.035
   PubMed Web of Science ®Google Scholar
• Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012; 3:1566-75; PMID:23248156
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-83; PMID:22966018; http://dx.doi.org/10.1158/1078-0432.CCR-12-1627
   PubMed Web of Science ®Google Scholar
• Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, et al. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget 2013; 4:772-84; PMID:23800712
   PubMed Web of Science ®Google Scholar
• Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, et al. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol 2013; 24:838-42; PMID:23139256; http://dx.doi.org/10.1093/annonc/mds524
   PubMed Web of Science ®Google Scholar